Clesrovimab (secondary prevention of RSV lower respiratory tract disease) – Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Clesrovimab (secondary prevention of RSV lower respiratory tract disease) – Benefit assessment according to §35a Social Code Book V

   published on

   01.09.2026

   Document type

   PDF document, 266 kB, DE, not accessible

   Download file : Extract of dossier assessment (PDF document, 266 kB, DE, not accessible)
2. Dossier assessment

   Clesrovimab (secondary prevention of RSV lower respiratory tract disease) – Benefit assessment according to §35a Social Code Book V

   published on

   01.09.2026

   Document type

   PDF document, 699 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/A26-67

   Download file : Dossier assessment (PDF document, 699 kB, DE, not accessible)

Dossier assessment

Project details

Project no.

A26-67

Commission

Commission awarded on 01.06.2026 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Immune system and infections

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A26-67